Expression of isocitrate dehydrogenase-1 in glioblastoma, Bangladesh perspective

Simple item page
dc.contributor.authorMir, R.en_US
dc.contributor.authorIslam, M. A.en_US
dc.contributor.authorIslam, N.en_US
dc.contributor.authorIslam, M. N.en_US
dc.contributor.authorDas, R.en_US
dc.contributor.authorKabir, E.en_US
dc.date.accessioned2024-09-24T09:20:38Z
dc.date.available2024-09-24T09:20:38Z
dc.date.issued2024-01
dc.description.abstractBackground: Glioblastoma is the most frequent malignant brain tumor in adults. Various studies have identified IDH (isocitrate dehydrogenase) mutation as a hallmark genetic alteration in glial tumors. The World Health Organization (WHO) has classified glioblastoma based on IDH mutation status, including IDH-mutant glioblastoma, IDH-wildtype glioblastoma along with its variants and glioblastoma, NOS (not otherwise specified) (where IDH mutation status cannot be evaluated). Methods: It was a cross-sectional observational study, conducted on 35 histologically diagnosed cases of glioblastoma, within the period of March, 2018 to December 2019. Results: Among the 35 glioblastoma cases, 6 (17.14%) were found to be IDH-mutant (positive for IDH1 immunostain), while the remaining 29 cases were negative for IDH1 immunostain (therefore designated as IDH-wildtype glioblastoma). In the IDH-mutant group, 3 out of 6 patients were in the younger age group (?40 years). On the other hand, IDH-wildtype glioblastoma was more common in elderly and most frequent was in the age group of 51-60 years (11 out of 29 cases). Conclusions: In this study, IDH1 expression was observed in 17.14% of all glioblastoma cases (designated as IDH-mutant glioblastoma). Whereas, most (~82.86%) of the glioblastoma cases did not express IDH1 (designated as IDH-wildtype).en_US
dc.identifier.affiliationsDepartment of Pathology, Sir Salimullah Medical College, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pathology, Dhaka Medical College, Dhaka, Bangladeshen_US
dc.identifier.affiliationsNational Institute of Neuroscience, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pathology, Sir Salimullah Medical College, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pathology, Sir Salimullah Medical College, Dhaka, Bangladeshen_US
dc.identifier.affiliationsDepartment of Pathology, Sir Salimullah Medical College, Dhaka, Bangladeshen_US
dc.identifier.citationMir R., Islam M. A., Islam N., Islam M. N., Das R., Kabir E.. Expression of isocitrate dehydrogenase-1 in glioblastoma, Bangladesh perspective. International Journal of Research in Medical Sciences. 2024 Jan; 12(1): 57-60en_US
dc.identifier.issn2320-6071
dc.identifier.issn2320-6012
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/233855
dc.languageenen_US
dc.publisherMedip Academyen_US
dc.relation.issuenumber1en_US
dc.relation.volume12en_US
dc.source.urihttps://doi.org/10.18203/2320-6012.ijrms20233977en_US
dc.subjectIDH1en_US
dc.subjectGlioblastomaen_US
dc.subjectBrain tumorsen_US
dc.titleExpression of isocitrate dehydrogenase-1 in glioblastoma, Bangladesh perspectiveen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijrms2024v12n1p57.pdf
Size:
485.16 KB
Format:
Adobe Portable Document Format
Download
Collections
International Journal of Research in Medical Sciences